The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase
Observational
Started
2018-01-01
Last updated
2022-12-20
Condition(s) studied
Lung Cancer
Investigational drug(s) / intervention(s)
Multiomics analysis
Multiomics analysis: Genome, proteomics, single cell RNA sequencing, and space transcriptome sequencing，etc
Study summary
The investigators plan to conduct a multiomics analysis（such as, Genomics, proteomics, single cell RNA sequencing, space transcriptomics）of tumor tissue and blood, aiming at analyzing tumor heterogeneity, mapping the microenvironment map of lung cancer and exploring the mechanism of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Histopathology or hemology diagnostics of lung cancer
* Patients have never received any antineoplastic therapy
Exclusion Criteria:
* Within 5 years or at the same time, there are other active malignancies
* Currently participating in interventional clinical research treatment, or received other research drugs or used research devices within 4 weeks before the first administration
* Active autoimmune diseases requiring systemic treatment (such as the use of disease relieving drugs, glucocorticoids or immunosuppressants) occurred within 2 years before the first administration
* The study was receiving systemic glucocorticoid treatment (excluding local glucocorticoids by nasal spray, inhalation or other means) or any other form of immunosuppressive therapy within 7 days before the first administration; Note: It is allowed to use glucocorticoid with physiological dose (prednisone ≤ 10mg/day or equivalent)
* Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation
Primary outcome measure(s)
objective response rate — three years Refers to the proportion of patients whose tumor shrinkage reaches a certain amount and remains for a certain period of time, including CR + PR cases
Major Pathologic Response — three-four months \<10% viable tumor in resected lung and lymph nodes
progression-free survival — three years Patients with oncological diseases have a period of time from the start of treatment to the observation of disease progression or death due to any cause
Trial sites (1)
Facility
City
Region
Status
The Fourth Affiliated Hospital of Zhejiang University
Yiwu
Zhejiang
Recruiting
More The Fourth Affiliated Hospital of Zhejiang University School of Medicine trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.